Cargando…
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon con...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366062/ https://www.ncbi.nlm.nih.gov/pubmed/37434099 http://dx.doi.org/10.1007/s13555-023-00969-1 |
_version_ | 1785077090192719872 |
---|---|
author | Gottlieb, Alice B. Burge, Russel Malatestinic, William N. Zhu, Baojin Zhao, Yunyang McCormack, Julie Kimel, Miriam Merola, Joseph F. |
author_facet | Gottlieb, Alice B. Burge, Russel Malatestinic, William N. Zhu, Baojin Zhao, Yunyang McCormack, Julie Kimel, Miriam Merola, Joseph F. |
author_sort | Gottlieb, Alice B. |
collection | PubMed |
description | INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon continuation for 24 weeks. OBJECTIVE: To describe patient-reported clinical and quality-of-life outcomes after initiating ixekizumab using data collected from the United States Taltz® Customer Support Program. METHODS: This was a 24-week prospective, observational study of commercially insured diagnosis-confirmed adults with PsO. Surveys were completed at weeks 0 (baseline), 2, 4, 8, 12, and 24 and included the Patient Report of Extent of Psoriasis Involvement questionnaire to assess the extent of body surface area (BSA) affected by PsO, itch and pain numeric rating scales, Patient Global Assessment of Disease Severity (PatGA), and Dermatology Life Quality Index (DLQI). RESULTS: 523 patients were included in the analysis. Proportions of patients with ≤ 2% BSA involvement were 34.5%, 40.1%, 50.9%, and 79.9% at weeks 0, 2, 4, and 24, respectively; 54.8% and 75.1% achieved National Psoriasis Foundation preferred (BSA ≤ 1%) and acceptable (BSA ≤ 3% or ≥ 75% improvement) responses at week 12, respectively. Improvements of ≥ 4 points in itch and pain were seen by week 2 in 21.1% and 28.0% of patients, respectively, which increased to 63.1% and 64.8% at week 24. Proportions of patients with PatGA scores of 0 (clear) or 1 were 13.4%, 24.1%, 34.0%, and 69.6% at weeks 0, 2, 4, and 24, respectively; and proportions with DLQI total scores of 0 or 1 [no or minimal impact] were 8.4%, 17.6%, 27.3%, and 53.8% at weeks 0, 2, 4, and 24, respectively. CONCLUSION: Patient-reported improvements in BSA, itch, skin pain, dermatology-specific quality of life, and overall PsO severity were seen as early as 2 weeks after initiation and continued through week 24. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-023-00969-1. |
format | Online Article Text |
id | pubmed-10366062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-103660622023-07-26 Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program Gottlieb, Alice B. Burge, Russel Malatestinic, William N. Zhu, Baojin Zhao, Yunyang McCormack, Julie Kimel, Miriam Merola, Joseph F. Dermatol Ther (Heidelb) Original Research INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon continuation for 24 weeks. OBJECTIVE: To describe patient-reported clinical and quality-of-life outcomes after initiating ixekizumab using data collected from the United States Taltz® Customer Support Program. METHODS: This was a 24-week prospective, observational study of commercially insured diagnosis-confirmed adults with PsO. Surveys were completed at weeks 0 (baseline), 2, 4, 8, 12, and 24 and included the Patient Report of Extent of Psoriasis Involvement questionnaire to assess the extent of body surface area (BSA) affected by PsO, itch and pain numeric rating scales, Patient Global Assessment of Disease Severity (PatGA), and Dermatology Life Quality Index (DLQI). RESULTS: 523 patients were included in the analysis. Proportions of patients with ≤ 2% BSA involvement were 34.5%, 40.1%, 50.9%, and 79.9% at weeks 0, 2, 4, and 24, respectively; 54.8% and 75.1% achieved National Psoriasis Foundation preferred (BSA ≤ 1%) and acceptable (BSA ≤ 3% or ≥ 75% improvement) responses at week 12, respectively. Improvements of ≥ 4 points in itch and pain were seen by week 2 in 21.1% and 28.0% of patients, respectively, which increased to 63.1% and 64.8% at week 24. Proportions of patients with PatGA scores of 0 (clear) or 1 were 13.4%, 24.1%, 34.0%, and 69.6% at weeks 0, 2, 4, and 24, respectively; and proportions with DLQI total scores of 0 or 1 [no or minimal impact] were 8.4%, 17.6%, 27.3%, and 53.8% at weeks 0, 2, 4, and 24, respectively. CONCLUSION: Patient-reported improvements in BSA, itch, skin pain, dermatology-specific quality of life, and overall PsO severity were seen as early as 2 weeks after initiation and continued through week 24. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-023-00969-1. Springer Healthcare 2023-07-11 /pmc/articles/PMC10366062/ /pubmed/37434099 http://dx.doi.org/10.1007/s13555-023-00969-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Gottlieb, Alice B. Burge, Russel Malatestinic, William N. Zhu, Baojin Zhao, Yunyang McCormack, Julie Kimel, Miriam Merola, Joseph F. Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program |
title | Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program |
title_full | Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program |
title_fullStr | Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program |
title_full_unstemmed | Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program |
title_short | Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program |
title_sort | ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: data from the united states taltz customer support program |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366062/ https://www.ncbi.nlm.nih.gov/pubmed/37434099 http://dx.doi.org/10.1007/s13555-023-00969-1 |
work_keys_str_mv | AT gottliebaliceb ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT burgerussel ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT malatestinicwilliamn ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT zhubaojin ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT zhaoyunyang ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT mccormackjulie ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT kimelmiriam ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram AT merolajosephf ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram |